PDF(Pubmed)
Abstract：
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.
摘要：
胰腺导管腺癌（PDAC）占所有胰腺癌的90％以上，是所有癌症中最致命的。联合化疗的治疗反应远不能令人满意，手术仍然是治疗策略的主要手段。这些挑战需要确定有效的治疗方法来对抗这种致命的癌症。PDAC肿瘤进展与凝血系统的稳健激活有关。值得注意的是,肿瘤相关血栓形成（CAT）是PDAC的重要危险因素。CAT是癌细胞促进血栓栓塞的概念，主要是静脉血栓栓塞（VTE）。在所有癌症类型中，PDAC与发生VTE的最高风险相关。PDAC肿瘤微环境中的缺氧也会增加血栓形成的风险。直接口服抗凝剂（DOAC）或低分子量肝素（LMWH）仅用作PDAC的血栓预防。然而,建议采用精准医学方法来确定临床上血栓预防的精确剂量和持续时间.
